Literature DB >> 14559738

Modelling hepatitis C virus incidence, prevalence and long-term sequelae in Australia, 2001.

Matthew G Law1, Gregory J Dore, Nicky Bath, Sandra Thompson, Nick Crofts, Kate Dolan, Wendy Giles, Paul Gow, John Kaldor, Stuart Loveday, Elizabeth Powell, Jenean Spencer, Alex Wodak.   

Abstract

BACKGROUND: To plan an appropriate public health response to the hepatitis C virus (HCV) epidemic requires that estimates of HCV incidence and prevalence, and projections of the long-term sequelae of infection, are as accurate as possible. In this paper, mathematical models are used to synthesize data on the epidemiology and natural history of HCV in Australia to estimate HCV incidence and prevalence in Australia to end 2001, and project future trends in the long-term sequelae of HCV infection.
METHODS: Mathematical models of the HCV epidemic in Australia were developed based on estimates of the pattern of injecting drug use. Estimates of HCV infections due to injecting drug use were then adjusted to allow for HCV infections resulting from other transmission routes. Projections of the long-term sequelae of HCV infection were obtained by combining modelled HCV incidence with estimates of the progression rates to these outcomes.
RESULTS: It was estimated that there were 210 000 (lower and upper limits of 157 000 and 252 000) people in Australia living with HCV antibodies at the end of 2001, with HCV incidence in 2001 estimated to be 16 000 (11 000-19 000). It was estimated that 6500 (5000-8000) people were living with HCV-related cirrhosis in 2001, that 175 (130-210) people developed HCV-associated liver failure, and that there were 50 (40-60) incident cases of HCV-related hepatocellular carcinoma (HCC). It was estimated that in 2001 22 500 quality adjusted life years were lost to chronic HCV infection, the majority (77%) in people with early (stage 0/1) liver disease. DISCUSSION: Model-based estimates were broadly consistent with other sources of information on the HCV epidemic in Australia. These models suggest that the prevalence of HCV-related cirrhosis and the incidence of HCV-related liver failure and HCC will more than triple in Australia by 2020.

Entities:  

Mesh:

Year:  2003        PMID: 14559738     DOI: 10.1093/ije/dyg101

Source DB:  PubMed          Journal:  Int J Epidemiol        ISSN: 0300-5771            Impact factor:   7.196


  25 in total

1.  Effects of reduction in heroin supply on injecting drug use: analysis of data from needle and syringe programmes.

Authors:  Carolyn Day; Louisa Degenhardt; Stuart Gilmour; Wayne Hall
Journal:  BMJ       Date:  2004-08-03

2.  Incident Hepatitis C Virus Genotype Distribution and Multiple Infection in Australian Prisons.

Authors:  Melanie R Walker; Hui Li; Suzy Teutsch; Brigid Betz-Stablein; Fabio Luciani; Andrew R Lloyd; Rowena A Bull
Journal:  J Clin Microbiol       Date:  2016-05-11       Impact factor: 5.948

3.  Hepatic and extra-hepatic sequelae, and prevalence of viral hepatitis C infection estimated from routine data in at-risk groups.

Authors:  Annunziata Faustini; Paola Colais; Emanuele Fabrizi; Anna Maria Bargagli; Marina Davoli; Domenico Di Lallo; Anteo Di Napoli; Patrizio Pezzotti; Chiara Sorge; Rita Grillo; Carla Maresca; Olga Recchia; Carlo A Perucci
Journal:  BMC Infect Dis       Date:  2010-04-19       Impact factor: 3.090

4.  Risk factors for hepatitis C infection and perception of antibody status among male prison inmates in the Hepatitis C Incidence and Transmission in Prisons Study cohort, Australia.

Authors:  Jennifer A Gates; Jeffrey J Post; John M Kaldor; Yong Pan; Paul S Haber; Andrew R Lloyd; Kate A Dolan
Journal:  J Urban Health       Date:  2004-09       Impact factor: 3.671

5.  Interleukin 12B gene polymorphism and apparent resistance to hepatitis C virus infection.

Authors:  D Hegazy; P Thurairajah; M Metzner; A Houldsworth; S Shaw; E Kaminski; A G Demaine; M E Cramp
Journal:  Clin Exp Immunol       Date:  2008-04-16       Impact factor: 4.330

6.  Treatment responses in Asians and Caucasians with chronic hepatitis C infection.

Authors:  Kenneth-K Yan; Marianne Guirgis; Thuy Dinh; Jacob George; Anouk Dev; Alice Lee; Amany Zekry
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

Review 7.  Modeling hepatitis C virus transmission among people who inject drugs: Assumptions, limitations and future challenges.

Authors:  Nick Scott; Margaret Hellard; Emma Sue McBryde
Journal:  Virulence       Date:  2015-08-25       Impact factor: 5.882

8.  An autoregressive integrated moving average model for short-term prediction of hepatitis C virus seropositivity among male volunteer blood donors in Karachi, Pakistan.

Authors:  Saeed Akhtar; Shafquat Rozi
Journal:  World J Gastroenterol       Date:  2009-04-07       Impact factor: 5.742

Review 9.  Epidemiology of hepatitis C virus infection.

Authors:  Miriam J Alter
Journal:  World J Gastroenterol       Date:  2007-05-07       Impact factor: 5.742

10.  A national cross-sectional study among drug-users in France: epidemiology of HCV and highlight on practical and statistical aspects of the design.

Authors:  Marie Jauffret-Roustide; Yann Le Strat; Elisabeth Couturier; Damien Thierry; Marc Rondy; Martine Quaglia; Nicolas Razafandratsima; Julien Emmanuelli; Gaelle Guibert; Francis Barin; Jean-Claude Desenclos
Journal:  BMC Infect Dis       Date:  2009-07-16       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.